Abstract
This study (NCT01288573) investigated plerixafor's safety and efficacy in children with cancer. Stage 1 investigated the dosage, pharmacokinetics (PK), pharmacodynamics (PD), and safety of plerixafor + standard mobilization (G-CSF ± chemotherapy). The stage 2 primary endpoint was successful mobilization (doubling of peripheral blood CD34+ cell count in the 24 h prior to first apheresis) in patients treated with plerixafor + standard mobilization vs. standard mobilization alone. In stage 1, three patients per age group (2-<6, 6-<12, and 12-<18 years) were treated at each dose level (160, 240, and 320 µg/kg). Based on PK and PD data, the dose proposed for stage 2 was 240 µg/kg (patients 1-<18 years), in which 45 patients were enrolled (30 plerixafor arm, 15 standard arm). Patient demographics and characteristics were well balanced across treatment arms. More patients in the plerixafor arm (24/30, 80%) met the primary endpoint of successful mobilization than in the standard arm (4/14, 28.6%, p = 0.0019). Adverse events reported as related to study treatment were mild, and no new safety concerns were identified. Plerixafor + standard G-CSF ± chemotherapy mobilization was generally well tolerated and efficacious when used to mobiliz...Continue Reading
References
Sep 11, 2002·FEBS Letters·Sigrid HatseDominique Schols
Jul 4, 2006·Biochemical Pharmacology·Simon P FrickerRebecca S Y Wong
Oct 14, 2008·Expert Opinion on Biological Therapy·Geoffrey L UyAmanda F Cashen
Jan 31, 2009·Nature Reviews. Drug Discovery·John F DiPersioPeter Kirkpatrick
Apr 14, 2009·Blood·John F DiPersioUNKNOWN 3102 Investigators
Oct 4, 2011·Drug Design, Development and Therapy·Boryana E AvramovaDragan G Bobev
Oct 20, 2011·Journal of Pediatric Hematology/oncology·Julián SevillaMaura Massimino
Mar 31, 2012·Journal of Hematology & Oncology·Kyung Taek HongHyo Seop Ahn
Jun 12, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Auayporn P NademaneeBrian J Bolwell
Dec 25, 2012·Cytotherapy·Julián SevillaMiguel Ángel Díaz-Pérez
Jan 22, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Richard T MaziarzBrian J Bolwell
Aug 3, 2013·American Journal of Hematology·Ivana N MicallefJohn F DiPersio
Apr 29, 2015·Bone Marrow Transplantation·A A MaschanM A Maschan
Apr 16, 2016·Transfusion·Ashley TeusinkSonata Jodele
Dec 20, 2017·Bone Marrow Transplantation·Mohamad MohtyKai Hübel
Jun 24, 2018·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Raphael TeipelFalk Heidenreich
Citations
Oct 21, 2020·Journal of Clinical Apheresis·Josune ZubicarayJulian Sevilla
Dec 9, 2020·Stem Cells and Development·Caroline HochheuserIlse Timmerman
Jan 22, 2021·Transfusion·Nabanita BhuniaHemalatha G Rangarajan
Sep 8, 2021·Pediatric Blood & Cancer·Jane KooChristopher E Dandoy